Literature DB >> 29595501

Pan-tuberculosis regimens: an argument for.

Robert S Wallis1, Ted Cohen2, Nicolas A Menzies3, Gavin Churchyard4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29595501     DOI： 10.1016/S2213-2600(18)30096-1

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  5 in total

Review 1.  Would pan-tuberculosis treatment regimens be cost-effective?

Authors:  Emily A Kendall; Grania Brigden; Christian Lienhardt; David W Dowdy
Journal:  Lancet Respir Med       Date:  2018-05-31       Impact factor: 30.700

2.  Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.

Authors:  Tawanda Gumbo; Carleton M Sherman; Devyani Deshpande; Jan-Willem Alffenaar; Shashikant Srivastava
Journal:  Int J Infect Dis       Date:  2021-02-05       Impact factor: 3.623

Review 3.  Quality of drug-resistant tuberculosis care: Gaps and solutions.

Authors:  Zarir Udwadia; Jennifer Furin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-04-24

Review 4.  Antibiotic resistance modifying ability of phytoextracts in anthrax biological agent Bacillus anthracis and emerging superbugs: a review of synergistic mechanisms.

Authors:  Mackingsley Kushan Dassanayake; Teng-Jin Khoo; Jia An
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-02       Impact factor: 3.944

5.  The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.

Authors:  Nimalan Arinaminpathy; Gabriela B Gomez; Kuldeep S Sachdeva; Raghuram Rao; Malik Parmar; Sreenivas A Nair; Kiran Rade; Sameer Kumta; David Hermann; Christy Hanson; Daniel P Chin; Puneet Dewan
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.